Dealing for infections

With positive Phase II data in hand for BC-3781, Nabriva Therapeutics AG believes it is well positioned to complete a deal for its lead antibiotic before entering Phase III. While pricing will likely keep generics as standard of care in the first-line setting to treat serious skin infections and pneumonia, Nabriva thinks BC-3781 can compete in second-line use given its broad spectrum of activity, novel mechanism of action and availability in both IV and oral formulations.

"There's a powerful case that you really have to try the generics first, because they are cheap and well understood," CEO David Chiswell noted...